Elmind Capital LP Invests $2.01 Billion in Amylyx Pharmaceuticals, Inc. $AMLX

Elmind Capital LP bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 112,000 shares of the company’s stock, valued at approximately $2,011,520,000. Amylyx Pharmaceuticals makes up approximately 0.5% of Elmind Capital LP’s holdings, making the stock its 28th biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $705,000. Dimensional Fund Advisors LP increased its position in shares of Amylyx Pharmaceuticals by 17.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company’s stock valued at $12,544,000 after purchasing an additional 131,944 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Amylyx Pharmaceuticals by 10.1% during the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock valued at $70,123,000 after purchasing an additional 531,162 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Amylyx Pharmaceuticals by 15.5% during the 1st quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company’s stock valued at $3,490,000 after buying an additional 33,757 shares during the period. Finally, Siren L.L.C. purchased a new stake in Amylyx Pharmaceuticals during the 1st quarter valued at $17,097,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX opened at $37.46 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $8.48 and a 52-week high of $41.14. The stock has a 50 day moving average price of $21.28 and a 200 day moving average price of $17.03. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of -26.20 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright upped their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Guggenheim increased their price objective on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $36.25.

Amylyx Pharmaceuticals Profile